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Abstract
Objectives
Severe mental illness (SMI) is associated with premature cardiovascular disease, prompting
the UK primary care payment-for-performance system (Quality and Outcomes Framework,
QOF) to incentivise annual physical health reviews. This study aimed to assess the QOF’s
impact on detection and treatment of cardiovascular risk factors in people with SMI.
Methods
A retrospective open cohort study of UK general practice was conducted between 1996 and
2014, using segmented logistic regression with 2004 and 2011 as break points, reflecting
the introduction of relevant QOF incentives in these years. 67239 SMI cases and 359951
randomly-selected unmatched controls were extracted from the Clinical Practice Research
Datalink (CPRD).
Results
There was strong evidence (p0.015) the 2004 QOF indicator (general health) resulted in
an immediate increase in recording of elevated cholesterol (odds ratio 1.37 (95% confidence
interval 1.24 to 1.51)); obesity (OR 1.21 (1.06 to 1.38)); and hypertension (OR 1.19 (1.04 to
1.38)) in the SMI group compared with the control group, which was sustained in subse-
quent years. Similar findings were found for diabetes, although the evidence was weaker
(p = 0.059; OR 1.21 (0.99 to 1.49)). There was evidence (p<0.001) of a further, but unsus-
tained, increase in recording of elevated cholesterol and obesity in the SMI group following
the 2011 QOF indicator (cardiovascular specific). There was no clear evidence that the
QOF indicators affected the prescribing of lipid modifying medications or anti-diabetic
medications.
Conclusion
Incentivising general physical health review for SMI improves identification of cardiovascular
risk factors, although the additional value of specifically incentivising cardiovascular risk
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factor assessment is unclear. However, incentives do not affect pharmacological manage-
ment of these risks.
Introduction
People with severe mental illnesses (SMI), including schizophrenia and bipolar affective disor-
der, are known to be at significant risk of premature morbidity and mortality. In the UK, indi-
viduals with SMI have a life expectancy around 12 years less than the general UK population,
[1] and similar disparities are seen in the US.[2] Cardiovascular disease is a major contributor
to this health inequality.[3]
The UK Quality and Outcomes Framework (QOF) aims to improve quality in primary care
through linking financial incentives to performance against indicators.[4] From its inception in
2004, the QOF has incentivised annual physical health review for people with SMI (S1 Appen-
dix). The nature of this review was unspecified until 2011, when more explicit cardiovascular
risk factor indicators were introduced; the majority of indicators were withdrawn in 2014.
To date there has been little evaluation of the impact of the QOF on the recognition and
management of cardiovascular risk factors in people with SMI. One study found the QOF
incentives reduced inequalities in cardiovascular risk factor testing between those with and
without SMI,[5] although the nature and time period of the analysis was relatively limited and
did not evaluate risk factor detection. Elsewhere the QOF has been shown to have increased
consultation rates[6] in people with SMI and also to have coincided temporally with an
increase in recording of comorbidities[6,7].
The current study builds on the above findings by exploring whether the QOF indicators
have been associated with improvements in the identification and management of cardiovas-
cular risk factors in people with SMI.
Methods
Anonymised data detailing diagnoses, prescribing, test results and demographics were
extracted from the Clinical Practice Research Datalink (CPRD). CPRD captures data recorded
by the general practitioner (GP) as part of routine care, and covers a 6.9% representative sam-
ple of the UK population.[8] Patients were included in the analysis during continuous periods
of registration at those participating practices which met CPRD’s internal quality standards.
The study was approved by the CPRD Independent Scientific Advisory Committee (protocol
reference 15_110RMn).
Study design
A retrospective open cohort design was used with cases having a lifetime SMI diagnosis and an
unmatched population comparison group without SMI. The study period included the conse-
cutive ’financial years’ from 1st April 1995 to 31st March 2014. Two interventions were consid-
ered: intervention 1 from April 2004 (introduction of the QOF SMI annual review indicator),
and intervention 2 from April 2011 (change to specific cardiovascular indicators).
Data from April 1995 to March 2003 were used to ascertain trends in the outcome before
the introduction of QOF. The 2003/04 year was excluded as per previous studies[6], as some
practices were preparing for the introduction of the QOF in the year prior to its introduction.
Within each year of analysis case and comparison group members could be eligible for the
full financial year or for a proportion of the year. The first day of inclusion in the analysis was
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the latest of the patient reaching age 35, first day of continuous registration, the patient’s GP
practice meeting CPRD’s data quality criteria, or (for cases) the date of SMI diagnosis. Eligibil-
ity for inclusion in the analysis ended at the first of having the outcome of interest, leaving the
practice, death, or the practice ceasing to submit data to CPRD.
Case and comparison group
Cases included all available patients aged35 years with a life-time diagnosis of SMI. SMI was
defined as schizophrenia, bipolar affective disorder, psychotic depression and other non-tran-
sient, non-organic psychoses. We identified Read codes corresponding to these conditions.
Code lists were based on previously published lists from the clinicalcodes.org repository[9],
supplemented by free-text searches for the aforementioned clinical terms. A snowballing
approach was then employed to identify additional terms similarly categorised in the Read
code hierarchy. Additional QOF codes were included to capture any change in coding practice
post-QOF. The resulting list of codes was reviewed by two clinicians to confirm the appropri-
ateness or otherwise of included codes, as well as identifying excluded diagnoses. As way of
validation, the prevalence of the resulting outcomes was checked against existing literature and
alternative published code lists. Patients with codes related to prodromal schizophrenia, to a
“single episode” or to a “reactive” episode were excluded, unless they also had a valid diagnos-
tic SMI code recorded. Code lists are available from the University of Bristol Research Data
Repository.[10]
The comparison group consisted of unmatched, randomly selected patients aged35 years
without SMI who had a period of continuous registration during the study period, aiming for
a minimum ratio of controls to cases of 5:1. Patients were excluded if they had ever been pre-
scribed medication used in the treatment of SMI, with the exception of those who had ever
had an epilepsy Read code recorded (i.e. when there is a likelihood of medication being used
as an anticonvulsant rather than a mood stabiliser).
We placed a restriction on the lower age limit of our population as outcomes are rare in
those under 35 years, and this improved our power to detect differences.
Clinical outcomes
We assessed four outcomes related to diagnosis and two related to treatment, which we con-
sidered of clinical importance and straightforward to measure using routine health-record
data: first ever recording of elevated serum cholesterol5.0mmol/L, first ever diagnosis of dia-
betes mellitus, first ever diagnosis/recording of obesity, first ever diagnosis of hypertension,
first ever prescription of anti-diabetic medication, and first ever prescription of lipid-modify-
ing medication.
Hypertension and diabetes mellitus outcomes were identified by diagnostic and administra-
tive Read codes, elevated cholesterol by test results, obesity by Read codes or body mass index
values30.0kg/m2, and medications from product code lists identified from the CPRD dictio-
nary. A similar approach to code list development was employed as for the identification of
SMI.
Statistical analyses
Annual incidence rates were calculated for all six outcomes for the case and comparison
groups. The proportion of the financial year spent eligible for inclusion in the analysis by each
patient was combined to create a denominator of ’person-years’ active for each financial year
for both groups.
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For all outcomes an interrupted time series analysis (ITSA) was performed. This approach
is recognised to be amongst the strongest quasi-experimental approaches to intervention anal-
ysis.[11,12] ITSA utilises data collected over equally spaced time intervals before and after an
intervention. It assumes that, in the absence of the intervention, trends prior to the interven-
tion could have been extrapolated to predict future trends.
A mixed effect segmented logistic regression model was used for the ITSA, with the inclu-
sion of a random intercept to allow for variation between general practices. The ITSA model
has been described elsewhere[13] and can be extended to incorporate a control group, as
shown in S2 Appendix. Additional terms were added to allow analysis of the second interven-
tion (change to QOF SMI indicators in 2011) and potential confounding by age (categorised
using 40, 50 and 60 year cut-offs) and gender. Data manipulation was undertaken using
Stata13.0[14] and analyses were conducted in R (version 3.2.4) using the package lme4.[15]
Step changes occurring immediately after the intervention’s introduction are reflected in the
model intercept, with subsequent effects on the temporal trend reflected by the model slope.
Model fit was assessed by plotting the predicted probability of the outcome from the fitted
model against the observed probability of the outcome for the SMI and non-SMI groups (S3
Appendix).
We hypothesised that outcome measurements closer together in time may be more similar
than outcomes further apart. We used the Cumby-Huizinga test to explore the data for the
presence of this issue (autocorrelation), which may have resulted in part due to the grouping
of patients by general practice. The autocorrelation was almost zero and appeared to be negli-
gible (the test for lag orders 1 to 5 strongly accepted the null hypothesis of independence in
the series, as did the test at the individual lag). On account of the size of the dataset and com-
plexity of the statistical models, we therefore decided to take a parsimonious approach and not
account for potential autocorrelation in subsequent analyses.
Results
The number of patients and practices included varied with the growth of the CPRD dataset,
with 232, 595 and 530 practices contributing data in 1995/96, 2004/05 and 2013/14 respec-
tively. Numbers of patients and demographic characteristics are summarised in Table 1. A
total of 67,239 people with SMI and 359,951 people without SMI were included in the analysis,
with the former group typically providing fewer days of continuous data (1936 vs. 2703 days)
in part due to increased mortality.
Fig 1 shows the ITSA results. Numerical results are reported in Table 2 (detection of risk
factors) and Table 3 (treatment of risk factors). Following the incentivisation of annual reviews
for people with SMI in April 2004, there is strong evidence of an immediate increase (i.e. inter-
cept change) in the recording of elevated cholesterol.
Immediately after the intervention in 2004, the odds of an SMI patient having elevated cho-
lesterol test results are 1.21 (95% CI: 1.10–1.33) times higher, after the intervention in 2004.
These odds are 37% (95% CI: 24%-51%) higher than for a non-SMI patient. The results simi-
larly show increased recognition of diabetes (OR 1.21, 95% CI: 0.99–1.49), obesity (OR 1.21,
95% CI: 1.06–1.38) and hypertension (OR 1.19, 95% CI: 1.04–1.38), in the SMI compared to
the non-SMI group (Table 2).
A relative change over time coinciding with the 2004 QOF incentives was seen only for ele-
vated cholesterol (OR 1.03, 95% CI: 1.00–1.05), whereas the remainder saw no relative change
in gradient from 2004 to 2010, suggesting the immediate effects observed were sustained.
The introduction of cardiovascular specific SMI indicators in 2011 was associated with fur-
ther immediate increases (i.e. changes in intercept) in recognition of cases of elevated
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cholesterol (OR 1.84, 95% CI: 1.72–1.97) and obesity (OR 1.39, 95% CI: 1.26–1.53) relative to
the non-SMI group. However, this increase was not sustained over the following two years
that the incentives remained in place, with significant reducing trends relative to the non-SMI
group. No added improvements in case-finding of diabetes or hypertension were found in
association with the 2011 incentives.
Prescribing of both anti-diabetic and lipid-modifying medications increased significantly
over the study period, and to a greater extent in the SMI group. There was no evidence that
these changes were related to the QOF indicators introduced in 2004 (Table 3). The SMI indi-
cator introduced in 2011 was also not found to be associated with an increase in prescribing of
anti-diabetic medications in the SMI group relative to the non-SMI group.
Following the 2011 QOF SMI incentives, there was also no strong evidence of an immediate
change in prescribing of lipid modifying medications. There was some indication that the
change in the effect of time attributable to the 2011 QOF indicator differed for the SMI group
compared to the non-SMI group (OR 0.94, 95% CI: 0.89–0.99).
In the early years of the study there was a second peak in age of diagnosis of SMI in older
patients (60 years) which was absent following the introduction of QOF, raising concerns
that a change in coding practice had influenced the findings. As a sensitivity analysis, we
removed patients whose age at first diagnosis of SMI was at least 60 years; this had little impact
on our findings (S4 Appendix). In addition, we conducted a falsification analysis, using fabri-
cated policy indicator years of 2000 and 2008 (S5 Appendix). There were no significant
changes in outcome observed in relation to these dates. The only exception was an apparent
change in recording of elevated cholesterol in 2008 but this was in the opposite direction to
that observed in the main 2011 analysis. These findings provide reassurance that the observed
changes in outcomes in the main analysis are indeed related to the QOF interventions.
Table 1. Demographic characteristics of patients with and without severe mental illness.
Year SMI Non-SMI
Number of patients 1995/96 6,395 59,476
2004/05 19,728 179,434
2013/14 23,775 174,306
Age in years, mean (SD) 1995/96 63.0 (SD 16.3) 56.0 (SD 14.6)
2004/05 57.6 (SD 14.9) 55.6 (SD 14.6)
2013/14 56.8 (SD 14.3) 56.7 (SD 14.5)
Male 1995/96 38.4% 48.9%
2004/05 45.2% 49.3%
2013/14 48.4% 49.0%
Socioeconomic deprivation (IMD quintile)
1 (least deprived) - 9.6% 15.0%
2 11.6% 15.0%
3 12.6% 12.8%
4 14.4% 11.7%
5 (most deprived) 15.0% 8.9%
Unavailable 36.8% 36.7%
Follow-up in days, mean (SD) - 1936 (SD 1785) 2703 (SD 2051)
SMI, severe mental illness; SD, standard deviation; IMD, Index of Multiple Deprivation. IMD quintile based
on the IMD score for relevant postcode in 2010 (unavailable for over a third of patients, including all patients
outside of England)
https://doi.org/10.1371/journal.pone.0179392.t001
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Discussion
We have found strong evidence that primary care incentives promoting physical health
reviews in patients with SMI can result in improvements in the identification but not treat-
ment of cardiovascular risk factors.
Fig 1. Outcomes over time for patients with and without severe mental illness. SMI, severe mental illness. Dashed vertical lines indicate the
introductions of the Quality of Outcomes Framework (QOF) in 2004 and 2011.
https://doi.org/10.1371/journal.pone.0179392.g001
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This study benefits from the use of robust methodology and external generalizability. In-
terrupted time series analysis with a comparison group is a powerful, pseudo-experimental
methodology that allows both the temporal trends prior to the intervention and any change
coinciding with the intervention to be taken into account. However, the study’s limitations
also require consideration. First, it is not possible to distinguish improved case finding from
Table 2. Interrupted time series analyses results, reporting immediate changes in detection of cardiovascular risk factors and changes over time.
Odds ratio (95% confidence interval)
SMI Non-SMI Difference p value*
Serum cholesterol 5.0mmol/L
Intervention 1 Change in intercept 1.21 (1.10 to 1.33) 0.89 (0.86 to 0.92) 1.37 (1.24 to 1.51) <0.001
Change over time 0.80 (0.78 to 0.82) 0.78 (0.77 to 0.78) 1.03 (1.00 to 1.05) 0.030
Intervention 2 Change in intercept 1.95 (1.83 to 2.08) 1.08 (1.04 to 1.11) 1.84 (1.72 to 1.97) <0.001
Change over time 0.70 (0.67 to 0.73) 1.04 (1.02 to 1.06) 0.67 (0.65 to 0.70) <0.001
Diabetes mellitus
Intervention 1 Change in intercept 0.94 (0.78 to 1.13) 0.78 (0.71 to 0.85) 1.21 (0.99 to 1.49) 0.059
Change over time 0.90 (0.87 to 0.94) 0.88 (0.86 to 0.90) 1.02 (0.98 to 1.09) 0.286
Intervention 2 Change in intercept 1.08 (0.93 to 1.24) 1.00 (0.92 to 1.09) 1.08 (0.91 to 1.27) 0.391
Change over time 0.96 (0.88 to 1.04) 1.02 (0.97 to 1.07) 0.94 (0.85 to 1.03) 0.191
Obesity
Intervention 1 Change in intercept 1.30 (1.15 to 1.46) 1.07 (1.02 to 1.13) 1.21 (1.06 to 1.38) 0.005
Change over time 0.88 (0.86 to 0.91) 0.91 (0.90 to 0.92) 0.98 (0.95 to 1.00) 0.087
Intervention 2 Change in intercept 1.35 (1.24 to 1.47) 0.97 (0.92 to 1.02) 1.39 (1.26 to 1.53) <0.001
Change over time 0.85 (0.80 to 0.89) 0.98 (0.95 to 1.01) 0.87 (0.82 to 0.92) <0.001
Hypertension
Intervention 1 Change in intercept 1.47 (1.28 to 1.68) 1.23 (1.17 to 1.29) 1.19 (1.04 to 1.38) 0.015
Change over time 0.93 (0.90 to 0.96) 0.91 (0.90 to 0.92) 1.02 (0.99 to 1.05) 0.240
Intervention 2 Change in intercept 1.03 (0.90 to 1.17) 1.04 (0.98 to 1.10) 0.99 (0.85 to 1.14) 0.849
Change over time 1.02 (0.94 to 1.11) 1.11 (1.07 to 1.15) 0.92 (0.84 to 1.00) 0.055
Changes are reported for patients with and without severe mental illness, and the difference between the two groups. SMI, severe mental illness.
* p value for difference between groups
https://doi.org/10.1371/journal.pone.0179392.t002
Table 3. Interrupted time series analyses results, reporting immediate changes in treatment of cardiovascular risk factors and changes over time.
Odds ratio (95% confidence interval)
SMI Non-SMI Difference p value*
Anti-diabetic medication
Intervention 1 Change in intercept 0.90 (0.75 to 1.07) 0.91 (0.84 to 0.99) 0.98 (0.81 to 1.20) 0.864
Change over time 0.90 (0.87 to 0.94) 0.91 (0.89 to 0.93) 0.99 (0.95 to 1.043 0.587
Intervention 2 Change in intercept 1.01 (0.88 to 1.16) 1.00 (0.93 to 1.08) 0.98 (0.94 to 1.03) 0.423
Change over time 0.99 (0.91 to 1.07) 0.98 (0.94 to 1.03) 1.01 (0.92 to 1.10) 0.906
Lipid-modifying medications (including statins)
Intervention 1 Change in intercept 1.06 (0.93 to 1.22) 1.06 (1.01 to 1.11) 1.01 (0.987 to 1.16) 0.924
Change over time 0.73 (0.71 to 0.76) 0.75 (0.74 to 0.76) 0.98 (0.94 to 1.01) 0.187
Intervention 2 Change in intercept 1.05 (0.97 to 1.15) 0.97 (0.93 to 1.01) 1.10 (1.00 to 1.20) 0.053
Change over time 0.96 (0.92 to 1.01) 1.03 (1.00 to 1.06) 0.94 (0.89 to 0.99) 0.027
Changes are reported for patients with and without severe mental illness, and the difference between the two groups. SMI, severe mental illness.
* p value for difference between groups
https://doi.org/10.1371/journal.pone.0179392.t003
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genuine changes in incidence, although the latter are likely to happen gradually. It is also possi-
ble that the increases in diagnoses reflect improved recording as opposed to detection per se.
Nevertheless, we believe that recording of clinical information in electronic health records is
still likely to facilitate delivery of care, such as through improved case finding, and thus failure
to record a risk factor is for all practical purposes equivalent to failing to identify it in the first
place. In addition, laboratory values (e.g. cholesterol) are automatically populated from the
laboratory systems, and as such reflect genuine measurement and not simply recording. Sec-
ondly, we found differences in the age distribution of our SMI population in the earlier years
of the study, potentially reflecting changes in coding practice; a fall over time in the age at diag-
nosis of SMI has also been described elsewhere.[6] Nevertheless, we adjusted for age in our
analyses, and also found no notable differences when age was not accounted for by the models,
reassuring us that our findings are robust to this issue. Additional supplementary analyses,
excluding those with a first diagnosis of SMI at age 60 years or older, supports these findings.
Thirdly, ITSA may be rendered invalid by the presence of a confounder that changed in a time
period coinciding with the intervention. This is pertinent to the current study as the QOF tar-
geted other broad key health outcomes in the general population, some of which may also
have been relevant to people with SMI. This is accounted for by the inclusion of a comparison
group in the study design, although the assumption must be made that other health service
changes would impact on both groups equally. We are unaware of other major interventions
(e.g. clinical guidelines) that coincided temporally with the QOF changes. Although National
Service Frameworks were introduced in the early 2000s to set minimum standards for care in
areas including diabetes, we expect that the impact of this is likely to be small, as firstly our
study focuses on case identification rather than quality of care, and secondly there is no reason
to suspect it to have a significant differential impact on the two study groups. Fourthly, the
QOF SMI indicators introduced in 2011 relating to lipids and blood glucose/HbA1c testing
applied only to those aged 40 and over whilst cases aged 35 and over are included in this study.
This could have resulted in a slight underestimate of the true effect. Finally, the study is limited
by the small number of data points following the 2011 changes to the QOF SMI indicators. As
these indicators were in place for only 3 years, a more complete analysis including longer term
trends is impossible, although we believe our analysis probably still provides valid and useful
insights into the effect of the later intervention.
Under-recording of cardiovascular risk factors in the SMI population has been previously
reported[16] and it is thus reassuring that incentives appear to help address this. When specific
cardiovascular SMI indicators were introduced in 2011, people with SMI had already been
subject to annual reviews for seven years, meaning those most willing to attend reviews who
were at highest cardiovascular risk may already have been identified. This contextual differ-
ence makes it difficult to know whether there are differences in the effectiveness of the 2004
and 2011 indicators. Of note, the sharp increases in recording of both obesity and elevated
cholesterol in 2011 despite the seven preceding years of annual reviews perhaps suggest the
later cardiovascular-specific indicator resulted in a “catch-up” of previously undetected risk
factors; the subsequent drop in recording may reflect patients being tested in earlier years or
being otherwise harder to reach. Despite this, the levels of detection do not fall below the pre-
2011 trend for either elevated cholesterol or obesity. One must therefore be cautious about
both interpreting the initial improvement in 2011 as evidence of the superiority of a more spe-
cific incentive, and of interpreting the post-2011 decrease as meaning this indicator was either
not sustained or less effective than the indicators introduced in 2004. The majority of indica-
tors were withdrawn in 2014 meaning a more complete analysis of the 2011 indicators will not
be possible: it is not clear whether they were in place for sufficiently long to become usual
practice.
Financial incentives for cardiovascular risk factors in severe mental illness
PLOS ONE | https://doi.org/10.1371/journal.pone.0179392 June 9, 2017 8 / 11
The analysis suggests that the QOF SMI indicators have not affected prescribing of either
anti-diabetic or lipid-modifying medications. This is despite longstanding (i.e. pre-QOF),
readily available UK clinical guidance on pharmacotherapy for the associated risk factors
in the general population.[17] National guidance[18] advising clinicians to be aware of and
treat increased cardiovascular risk in SMI (specifically schizophrenia) patients has only been
available since 2009, but further work is nonetheless required to explore the reasons why the
increase in detection of risk factors is not matched by increased treatment. The findings are
consistent with studies describing under-treatment in this population in the presence of dysli-
pidaemia and hyperglycaemia[19] and in other areas such as stroke[20] and arthritis[21]. A
number of potential explanations for this have been proposed, including at the patient-level
(e.g. cognitive impairment, poor adherence), physician-level (e.g. stigmatization, complexity
of care), and service-level (e.g. fragmentation of care, lack of resources).[22] It is unclear
whether the increase in medication use due to the QOF prescribing incentives that has been
observed in the general population[23] would translate to an increase in prescribing if targeted
specifically at the SMI population.
A number of issues raised by this study merit further investigation. These include whether
or not more specific cardiovascular indicators offer additional value, patients’ and clinicians’
views on the role of SMI indicators, the reason that case detection was not followed by im-
provements in treatment, and whether there is value in specific incentives to encourage treat-
ment of physical problems in this population. However, what remains clear is that financial
incentives for GPs improve the detection of cardiovascular risk factors in a challenging patient
group in which identification of physical health problems is known to be poor. Incentives may
well have a broader role in reducing health inequalities and improving the care and treatment
of patients with severe mental illness.
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